1. Home
  2. AUPH vs MD Comparison

AUPH vs MD Comparison

Compare AUPH & MD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AUPH
  • MD
  • Stock Information
  • Founded
  • AUPH 1993
  • MD 1979
  • Country
  • AUPH Canada
  • MD United States
  • Employees
  • AUPH N/A
  • MD N/A
  • Industry
  • AUPH Biotechnology: Pharmaceutical Preparations
  • MD Hospital/Nursing Management
  • Sector
  • AUPH Health Care
  • MD Health Care
  • Exchange
  • AUPH Nasdaq
  • MD Nasdaq
  • Market Cap
  • AUPH 1.1B
  • MD 1.2B
  • IPO Year
  • AUPH 1999
  • MD 1995
  • Fundamental
  • Price
  • AUPH $9.04
  • MD $13.16
  • Analyst Decision
  • AUPH Strong Buy
  • MD Buy
  • Analyst Count
  • AUPH 2
  • MD 6
  • Target Price
  • AUPH $11.50
  • MD $16.67
  • AVG Volume (30 Days)
  • AUPH 2.0M
  • MD 609.8K
  • Earning Date
  • AUPH 07-31-2025
  • MD 08-05-2025
  • Dividend Yield
  • AUPH N/A
  • MD N/A
  • EPS Growth
  • AUPH N/A
  • MD N/A
  • EPS
  • AUPH 0.27
  • MD N/A
  • Revenue
  • AUPH $247,295,000.00
  • MD $1,976,177,000.00
  • Revenue This Year
  • AUPH $12.15
  • MD N/A
  • Revenue Next Year
  • AUPH $18.34
  • MD $3.26
  • P/E Ratio
  • AUPH $34.04
  • MD N/A
  • Revenue Growth
  • AUPH 29.20
  • MD N/A
  • 52 Week Low
  • AUPH $5.20
  • MD $6.96
  • 52 Week High
  • AUPH $10.67
  • MD $17.67
  • Technical
  • Relative Strength Index (RSI)
  • AUPH 64.76
  • MD 38.96
  • Support Level
  • AUPH $7.36
  • MD $13.34
  • Resistance Level
  • AUPH $9.10
  • MD $13.68
  • Average True Range (ATR)
  • AUPH 0.45
  • MD 0.42
  • MACD
  • AUPH 0.12
  • MD -0.06
  • Stochastic Oscillator
  • AUPH 96.69
  • MD 22.83

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

About MD Pediatrix Medical Group Inc.

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

Share on Social Networks: